Actinium-225

Nusano Expands Executive Management to Support Q1 2025 Radioisotope Commercialization

Retrieved on: 
星期三, 五月 29, 2024
Novartis, API, Health, Risk, Bedekar, CFO, Drug development, Cancer, Physics, Treasury, Medicine, Regulatory affairs, Radionuclide, Quality assurance, Actinium-225, Pharmaceutical industry

These appointments provide additional leadership and experience as the company begins commercial-scale radioisotope shipments to customers in Q1 2025.

Key Points: 
  • These appointments provide additional leadership and experience as the company begins commercial-scale radioisotope shipments to customers in Q1 2025.
  • “Nusano continues to attract best-in-class talent as we revolutionize radioisotope production to supply the fight against cancer,” said Chris Lowe, CEO of Nusano.
  • Their combined expertise and talents will be instrumental as we continue to expand our capabilities and prepare for commercialization beginning in Q1 2025."
  • The company expects to begin producing and delivering commercial-scale quantities of lutetitum-177 in Q1 2025 and actinium-225 in H2 2025.

Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer

Retrieved on: 
星期二, 五月 21, 2024
ASX, PET, Hook effect, Isotope, Patient, Pharmacokinetics, Liver, Data, PSMA, Safety, Bone marrow, TAT, TLX, Blood, Prostate cancer, Positron emission tomography, System, Kinetics, Actinium-225, Vaccine

CUPID is a Phase I safety and dosimetry study of TLX592, Telix’s investigational antibody-based targeted alpha therapy for prostate cancer.

Key Points: 
  • CUPID is a Phase I safety and dosimetry study of TLX592, Telix’s investigational antibody-based targeted alpha therapy for prostate cancer.
  • Successful completion of mass dose escalation study establishes a baseline dosing schedule for future studies of TLX592 using actinium-225.
  • MELBOURNE, Australia, May 21, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the successful completion of CUPID1, a first-in-human Phase I dose escalation study of TLX592 in patients with advanced prostate cancer.
  • TLX592 (225Ac-PSMA-RADmAb®) is Telix’s investigational “next generation” targeted alpha therapy (TAT) for the treatment of prostate cancer and is the first clinical program to utilise Telix’s proprietary RADmAb® engineered antibody technology.

Abdera Therapeutics Announces FDA Clearance of IND Application for ABD-147

Retrieved on: 
星期四, 五月 23, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, SCLC, Patient, Investigational New Drug, Toxicity, Food, Therapy, IND, Safety, Radiation, Cancer, Carcinoma, Tissue, DLL3, Actinium-225, Glomus tumor, Pharmaceutical industry

Abdera plans to initiate a Phase 1 clinical trial in the second half of 2024.

Key Points: 
  • Abdera plans to initiate a Phase 1 clinical trial in the second half of 2024.
  • ABD-147 is a next-generation precision radiopharmaceutical biologic therapy designed to deliver Actinium-225 (225Ac), a highly potent alpha-emitting radioisotope, to solid tumors expressing DLL3.
  • DLL3 is a protein found on the surface of neuroendocrine tumors, but rarely expressed on the surface of normal cells or tissues.
  • “FDA clearance of our first IND marks a major milestone for Abdera as we transition into a clinical-stage radiopharmaceutical company,” said Lori Lyons-Williams, president and chief executive officer.

Bayer Starts Phase I Study With Novel Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer

Retrieved on: 
星期三, 五月 15, 2024
Research, Fitness & Nutrition, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Patient, Survival, Surgery, PSMA, Prostate cancer, University, AACR, FRCS, Trial of the century, Disease, Université de Montréal, Safety, Gland, Horizon, MD, CHUM, Cancer, Professor, Bayer, Actinium-225, Pharmaceutical industry

Bayer announced today initiation of dosing in a Phase I first-in-human clinical study with 225Ac-PSMA-Trillium (BAY 3563254), a next-generation targeted alpha therapy.

Key Points: 
  • Bayer announced today initiation of dosing in a Phase I first-in-human clinical study with 225Ac-PSMA-Trillium (BAY 3563254), a next-generation targeted alpha therapy.
  • The dose-escalation study ( NCT06217822 ) will evaluate the safety, tolerability and efficacy of 225Ac-PSMA-Trillium in patients with advanced metastatic castration resistant prostate cancer (mCRPC).
  • “We are excited to announce initiation of the phase I and dosing of the first patient with 225Ac-PSMA-Trillium.
  • With its unique design, we believe it could offer a meaningful benefit for patients with metastatic prostate cancer, and we look forward to advancing the program through clinical development.”
    Prostate cancer is the second most commonly diagnosed cancer in men1 and a key area of focus at Bayer.

Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Retrieved on: 
星期一, 五月 13, 2024
Molecular imaging, Patient, Exposure, Bone marrow, BMT, SNMMI, Synthase, TP53, CD33, Radiation, AML, Nuclear medicine, ARC, Large, Abstract, Actinium-225, CD45, Annual general meeting, Medical imaging

NEW YORK, May 13, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that five abstracts have been accepted for presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting being held June 8 – 11, 2024, in Toronto, Canada. The abstracts will feature results from the Phase 3 SIERRA trial of Iomab-B, a CD45 targeting ARC with the Iodine-131 payload, intended for conditioning to prepare patients for a potentially curative bone marrow transplant (BMT) and results from a Phase 1b trial of Actimab-A, a CD33 targeting ARC with the Actinium-225 payload, in combination with the chemotherapy regimen CLAG-M.  Iomab-B and Actimab-A are the only targeted radiotherapies in development for patients with relapsed/refractory acute myeloid leukemia (r/r AML), a blood cancer that is highly sensitive to radiation. In addition, an abstract detailing proprietary linker technology applicable for solid tumor targeting ARCs developed by Actinium will be presented for the first time.

Key Points: 
  • In addition, an abstract detailing proprietary linker technology applicable for solid tumor targeting ARCs developed by Actinium will be presented for the first time.
  • Sandesh Seth, Actinium's Chairman and CEO, said, "Our presence at this year's SNMMI showcases the breadth of Actinium's capabilities and leadership in the development of Antibody Radiation Conjugates.
  • We look forward to highlighting the potential for targeted radiotherapy in blood cancers to the nuclear medicine community, which represents a significant expansion opportunity for the field.
  • Actinium's SNMMI presentations are detailed below:
    Mathematical Modeling of Exposure Measurements Following High-Dose Targeted Therapy Using 131I-apamistamab: Analysis From the Large Multicenter Phase III SIERRA Trial

Nusano to Present at Jefferies Radiopharma Innovation Summit

Retrieved on: 
星期三, 四月 10, 2024
Actinium-225, Jefferies, Physics

VALENCIA, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of medical radioisotopes, today announced it will attend and present at Jefferies Radiopharma Innovation Summit in New York City on Thursday, April 11, 2024.

Key Points: 
  • VALENCIA, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of medical radioisotopes, today announced it will attend and present at Jefferies Radiopharma Innovation Summit in New York City on Thursday, April 11, 2024.
  • In his presentation, Nusano CEO Chris Lowe will provide an update on the company’s commercialization plans, including programs to make lutetium-177 and actinium-225 available on a commercial scale in 2025.
  • Nusano management will also be available for 1-on-1 meetings.
  • To request a meeting, qualified investors should contact their Jefferies representative or email [email protected] .

Telix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.

Retrieved on: 
星期四, 四月 11, 2024
Health, Transport, Logistics, Supply Chain Management, Health Technology, Pharmaceutical, Biotechnology, USD, Isotope, BC Cancer Agency, Actinium-225, PET, History, Cyclotron, Patient, GHS, Acquisition, Lawson Health Research Institute, TRIUMF

ARTMS Inc. (ARTMS) is pleased to announce that the acquisition by Telix Pharmaceuticals Limited (Telix) has been completed.

Key Points: 
  • ARTMS Inc. (ARTMS) is pleased to announce that the acquisition by Telix Pharmaceuticals Limited (Telix) has been completed.
  • This acquisition further enhances the vertical integration of Telix’s supply chain and manufacturing by providing a greater level of supply chain and regulatory control over the production of key isotopes.
  • The history of ARTMS is rooted in a Canadian government funded project focused on solid target production of 99mTc.
  • Solomon Partners Securities LLC acted as financial advisor and Norton Rose Fulbright Canada LLP acted as legal advisor to ARTMS during the negotiations and due diligence process related to the acquisition by Telix.

Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments

Retrieved on: 
星期四, 三月 28, 2024
Cancer, Receptor (biochemistry), Radionuclide, Patient, Neoplasm, PET, G&A, Worldwide Angel, Actinium-225, MTIC, Pancreatic cancer, Investment, Fifth, Therapy, Clinical trial, Safety

WILMETTE, Ill., March 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced fourth quarter and full-year 2023 financial results and summarized recent developments.

Key Points: 
  • WILMETTE, Ill., March 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced fourth quarter and full-year 2023 financial results and summarized recent developments.
  • Results for the Fourth Quarter and Year Ended December 31, 2023, Compared to the Fourth Quarter and Year Ended December 31, 2022
    Cash, cash equivalents and short-term investments as of December 31, 2023, were $7.3 million.
  • R&D expenses for the fourth quarter of 2023 were $1.0 million compared to $2.1 million for the fourth quarter of 2022.
  • G&A expenses for the fourth quarter of 2023 were $0.9 million, compared to $0.8 million for the fourth quarter of 2022.

Nusano to Present Isotope Production Capabilities and Commercialization Plans at 7th Theranostics World Congress

Retrieved on: 
星期三, 三月 20, 2024
Actinium-225, Physics, Patient, Cancer

VALENCIA, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of medical radioisotopes, will present at the 7th Theranostics World Congress taking place March 22-24, 2024, in Santiago, Chile.

Key Points: 
  • VALENCIA, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of medical radioisotopes, will present at the 7th Theranostics World Congress taking place March 22-24, 2024, in Santiago, Chile.
  • Greg Moffitt, Nusano Director of Target Development, will provide an overview of the company’s proprietary radioisotope production platform on Sunday, March 24.
  • He will discuss Nusano’s plans to supply commercial-scale lutetium-177 beginning in early 2025 and to make the short-lived radioisotope, astatine-211, viable for therapeutic use.
  • “Nusano is bringing our commercial-scale, proprietary technology online to support cancer patients, stabilize supply chains and enable innovation,” said Greg Moffitt, Director of Target Development at Nusano.

RLS Radiopharmacies Partners with Eckert & Ziegler to Expand Production of Gallium-68-Based Radiopharmaceuticals

Retrieved on: 
星期四, 四月 4, 2024
Oncology, Medical Devices, Health, Radiology, Pharmaceutical, Biotechnology, Gallium, Diagnosis, Radionuclide, Glomus tumor, Prostate cancer, USP, Half-life, Actinium-225, Partnership, Patient, Pharmacy, RLS, PET, Splenic infarction, Cancer, SDAX, Radiopharmaceutical, Investment, Cyclotron, ISO, Positron emission tomography, DSM-IV codes, Gelastic seizure, Medical imaging

Under the partnership, all 31 of RLS’s radiopharmacies will be equipped with Eckert & Ziegler’s advanced GalliaPharm® generators, which the radiopharmacy network will utilize to produce high-quality, life-enhancing Gallium-68-based (Ga-68) radiopharmaceuticals.

Key Points: 
  • Under the partnership, all 31 of RLS’s radiopharmacies will be equipped with Eckert & Ziegler’s advanced GalliaPharm® generators, which the radiopharmacy network will utilize to produce high-quality, life-enhancing Gallium-68-based (Ga-68) radiopharmaceuticals.
  • “A powerful diagnostic isotope, Gallium has an extremely short half-life, necessitating the need for Ga-68-based radiopharmaceuticals to be produced within minutes of patient dosing.
  • This signifies a major leap forward in our commitment to advancing healthcare and improving patient outcomes through cutting-edge radiopharmaceuticals."
  • To date, RLS has installed Eckert & Ziegler’s GalliaPharm® generators within most of its locations and anticipates the remaining radiopharmacies will be operational by the end of June.